

Cancer Cachexia in Pancreatic Cancer Patients: Recent Advances and New Therapeutic Approach

Sang Hoon Lee^{1,2}, Moon Jae Chung^{1,2}

*Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine¹,
Pancreatobiliary Cancer Center, Yonsei Cancer Hospital², Seoul, Korea*

About 80% of all pancreatic cancer patients suffer from a wasting syndrome defined as the cancer cachexia characterized by abnormally low weight, weakness, and loss of skeletal muscle mass, which directly impacts physical activity, quality of life and overall survival. Over the past decades, we have gained new insights into the underlying mechanism of cachexia associated with pancreatic cancer. The aim of this review was to explore recent findings about cancer cachexia pathophysiology and describe the current pharmacologic approach. Pancreatic cancer cachexia is a multifactorial syndrome mediated by mechanical factors, inflammatory cytokines, neuropeptides, hormones and tumor-derived factors. The treatment of cancer cachexia remains controversial but is currently an active area of research. Several new targeted drugs are under investigation, and we hope to open a new prospect in the management of cancer cachexia in the future.

Key Words: Anorexia-cachexia syndrome, Pancreatic cancer cachexia, Pancreatic adenocarcinoma

INTRODUCTION

Cachexia is a multifactorial syndrome with ongoing loss of skeletal muscle mass, with or without loss of fat mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.¹ It can occur in the course of chronic benign disease such as congestive heart failure or human immunodeficiency virus (HIV) infection. However, it is most frequently observed in patients with malignancy, especially in advanced stage of disease. Many patients with advanced cancer suffer from a wasting syndrome characterized by anorexia, loss of weight, sarcopenia, and a poor prognosis, defined as the cancer anorexia-cachexia syndrome.²

Cachexia is highly prevalent in pancreatic cancer, and up to 80% of pancreatic cancer patients undergo severe cachexia at the time of death.^{3,4} This wasting syndrome is related with poor tolerability of cancer treatment, and furthermore, it can

reduce quality of life and expected survival of the patients.⁵⁻⁷ In addition, preoperative existence of cachexia in pancreatic cancer patients has been associated with poor outcome after pancreatoduodenectomy.⁸

Although new insights into the pathogenesis of cancer cachexia have been gained over the past decades, the underlying mechanisms are still poorly understood. It is currently to be an active area of research for potential treatment targets of cancer cachexia. We believed that improvement in overall survival or quality of life in pancreatic cancer patients could be achieved from a better management of cachexia. This article reviews the current concepts and therapeutic approach of this disabling phenomenon.

1. Definition and classification of cancer cachexia

The consensus diagnostic criteria of cancer cachexia defined as a case of (1) involuntary weight loss more than 5% in the last 6 months if no starvation present; (2) weight loss more than 2% in individuals with body mass index (BMI) less than 20 kg/m²; or (3) weight loss more than 2% along with skeletal muscle index (SMI) consistent with sarcopenia (males <7.26 kg/m², females <5.45 kg/m²) (Table 1). Any direct measure of skeletal muscle mass (dual-energy X-ray absorptiometry (DEXA), computed tomography (CT), magnetic resonance imaging (MRI)) is recommended in case of fluid retention, massive tumor load or obesity.⁹

Received: December 16, 2015

Accepted: December 21, 2015

Corresponding author: **Moon Jae Chung**, MD, PhD
Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.

Tel: +82-2-2228-1981, Fax: +82-2-393-6884

E-mail: mjchung@yuhs.ac

This international consensus also described three stages of cachexia; precachexia, cachexia, and refractory cachexia.⁹ Severity is based on the degree of depletion of energy store and body protein mass (using BMI) and the rate of ongoing weight loss. In precachexia, patients with early clinical and metabolic signs including anorexia and impaired glucose tolerance can precede considerable involuntary weight loss. Some patients then have progressive weight loss and meet the criteria for cachexia as previously defined. Large retrospective cohort study for pancreatic cancer revealed that a reduction in BMI developed as early as 3 years prior to cancer diagnosis and cachexia-associated symptoms presented at average 2

months before the cancer diagnosis.^{10,11} Unfortunately, most patients with pancreatic cancer usually demonstrate in the advanced stage with cachexia symptoms,¹² and their cachexia becomes clinically refractory as a result of progressive unresponsive to cancer treatment. In refractory cachexia stage, patients have worsening performance status with expected survival less than 3 months.

2. Pathophysiology of cancer cachexia

Cancer cachexia arises from a complex interaction between cancer growth and host response resulting ongoing weight loss, a consequence of a negative protein and energy balance mediated by a combination of reduced food intake and increased metabolism.^{1,9} The pathophysiology includes a series of complex metabolic mechanisms directly related to the tumor-host interaction (Fig. 1). There are mechanical factors that contribute to reduced food intake, tumor-derived factors released from the tumor itself and humoral factors generated as the host's biological response to the tumor. Several pro-inflammatory cytokines, circulating hormones, neuropeptides,

Table 1. Diagnosis of cancer cachexia

Weight loss greater than 5% over the past 6 months; or
Weight loss greater than 2% in individuals with BMI less than 20 kg/m²; or
Evidence of sarcopenia*withweightlossgreaterthan 2%

*Sarcopenia defined as appendicular skeletal muscle index in males <7.26 kg/m² and in females <5.45 kg/m² determined by DEXA.




Fig. 1. Pathophysiology of cachexia in pancreatic cancer. There are several factors which contribute to develop cachexia in pancreatic cancer, including mechanical factors, tumor-derived factors, humoral factors and neuronal invasion. Several pro-inflammatory cytokines, circulating hormones, neuropeptides, and neurotransmitters result in anorexia and metabolic alteration, such as increased lipolysis, proteolysis, lipid mobilization and energy.

*Adapted from Tan et al. Front Physiol 2014;5:88.1

and neurotransmitters can affect the development of cancer cachexia.¹³ In addition recent studies have described the other potentially momentous processes involved in the development of pancreatic cancer cachexia, including astrocytic activation from neural invasion of pancreatic cancer.^{14,15}

3. Mechanical factors

Mechanical digestive abnormalities that can reduce food intake and result in a lack of appetite include abdominal pain, nausea, dysphagia,odynophagia, pancreatic insufficiency, constipation, and intestinal obstruction.¹⁶ They can induce and maintain cancer-associated weight loss. These symptoms result from direct cancer invasion to pancreatic duct and/or gastrointestinal tract, particularly the duodenal second portion. Also, some patients who received the resection of pancreas suffer from pancreatic insufficiency and poor oral intake.

4. Humoral factors

The humoral mediators of cancer cachexia include pro-inflammatory cytokines (interleukin-1 (IL-1), interleukin-6 (IL-6), interferon- γ (IFN- γ), tumor necrosis factor- α (TNF- α), neuropeptides (neuropeptide Y, serotonin, melanocortin) and hormones (insulin, glucagon, leptin). These pathways can be divided into central pathways, which are controlled at brain hypothalamus, and peripheral pathways, which associate with direct lipolysis and proteolysis.

1) Centrally-mediated pathways

Recent evidence suggests that systemic inflammation plays a pivotal role in inducing cancer anorexia by triggering a complex neurochemical pathways in hypothalamus.^{17,18} Increased cytokine expression prevents the activation of hypothalamus from responding appropriately to peripheral signals by persistent stimulation of anorexigenic pathways and inhibition of orexigenic pathways.^{19,20} Some studies reveal that cancer cachexia is associated with hyperactivation of the pro-opiomelanocortin (POMC)/cocaine and amphetamine-regulated transcript (CART) pathways (one of anorexigenic pathways) which may be triggered by IL-1 and other pro-inflammatory cytokines.²¹⁻²⁴

Leptin is a protein with homeostatic effect released by fatty tissue, which reduces appetite and increase energy expenditure through the central nervous system (CNS). In situation of weight loss, leptin release is decreased and this stimulation the appetite in the CNS by activation of neuropeptide Y (NRY)/Agouti-related peptide (AgRP) pathway (one of orexigenic path-

ways) and reduced activity of anorexigenic neuropeptide, such as corticotropin-releasing factor (CRF) and melanocortin. Current studies for cancer cachexia suggest that inflammatory cytokine like IL-1 and TNF- α activate the leptin signaling and disturb the orexigenic response to decreased peripheral leptin level.^{19,25}

Serotonin also may play an important role in the development of cancer anorexia through the melanocortin system. Studies suggested that IL-1 stimulates the release of hypothalamic serotonin, which contribute to the persistent activation of POMC/CARD pathway, resulting in decreased appetite and anorexia.^{26,27}

2) Peripheral pathways

Inflammatory cytokines not only contribute to the neurochemical changes in the CNS responsible for anorexia, but also have been revealed to induce proteolysis, lipolysis, and the hepatic acute phase protein response (APPR) through the numerous pathways. These processes develop the uncompensated loss of muscle and adipose tissue.

TNF- α is one of the first identified as an endogenous cachexia-inducing factors. TNF- α stimulates protein degradation in the proteasome-ubiquitin system, mediated by transcription factors, such as nuclear factor kappa B (NF- κ B) and MyoD.²⁸⁻³⁰ Some studies also showed that TNF- α promote lipolysis in vitro with increase in glycerol release in mouse and human adipocyte, through downregulation of perilipin expression, which subsequently induce hormone-sensitive lipase (HSL), a key regulator of lipolysis, to access the surface of lipid droplets for breakdown.^{31,32} Additionally, TNF- α has a inhibitory action on adipocyte differentiation, resulting in impaired lipogenesis.^{33,34}

IL-6 is another important cytokine in the development of cachexia in pancreatic cancer, particularly associated with activation of the hepatic APPR. Moses et al found that overproduction of IL-6 and elevated APPR (for example; elevated c-reactive protein (CRP) level) have been significantly associated with decreased survival in patients with pancreatic cancer cachexia.³⁵ There is strong relationship between increased IL-6 production of peripheral blood mononuclear cells and the presence of elevated APPR.³⁵⁻³⁷ The activation of hepatic APPR promote the mobilization of peripheral amino acid stores, mostly from skeletal muscle, contributing to the loss of lean body mass.

5. Tumor factors

In addition to several humoral factors such as cytokines,

hormones and neurotransmitters, tumor-derived factors contribute to metabolic dysregulation in pancreatic cancer cachexia. There are two most well studied factors, lipid mobilizing factor (LMF) and proteolysis-inducing factor (PIF).

LMF was first discovered from a cachexia-inducing murine tumor model and the urine of patients with unresectable pancreatic cancer with weight loss.³⁸ This material was 43 kDa and was suggest to be homologous with the plasma protein zinc- α_2 -glycoprotein (ZAG).³⁸ LMF/ZAG not only induces lipid mobilization through various signal pathways but also augment substrate utilization and activates mitochondrial oxidative pathways in brown adipose tissue. Consequently, LMF/ZAG causes lipolysis with increased energy expenditure, and catabolism.³⁹⁻⁴¹ Recently, LMF/ZAG is proposed as a serum biomarker in pancreatic cancer cachexia.⁴²

PIF was isolated in 1996 from a mouse tumor model of cachexia, as a 24 kDa glycoprotein inducing skeletal muscle catabolism.⁴³ PIF was detected in the urine of 80% of pancreatic cancer patients with cachexia, and rate of weight loss was greater in patients who have PIF in their urine.⁴⁴ Also, when PIF from urine of cancer cachexia patients administered intravenously to normal mice, PIF induced significant weight loss without reduction in food and water intake.⁴⁵ Some studies suggest that PIF-mediated protein degradation may be mediated by the ubiquitin-proteasome proteolytic pathway in skeletal muscle; that process results from activation of NF κ B.⁴⁶⁻⁴⁸ Also, PIF inhibits the protein synthesis on skeletal muscle through activation of double-stranded RNA dependent protein kinase (PKR).⁴⁹

6. Other mechanisms

Recent studies have suggested that neural invasion of pancreatic cancer is related to astrocyte activation and development of cachexia in pancreatic cancer patients.^{14,15} Neuronal invasion of pancreatic cancer induce the activation of astrocytes and microglia in the spinal cord. These activated astrocytes can subsequently develop lipolysis and muscle atrophy in pancreatic cancer patients, although more researches is needed to determine the underlying mechanisms involving cachexia.¹⁴

7. Treatment of cancer cachexia

The primary end-points of optimal treatment of cancer cachexia are improvements in cachexia-associated symptoms such as anorexia and fatigue, lean body mass, resting energy expenditure, quality of life, and performance status through inhibition of effect of pro-inflammatory cytokines.⁵⁰ Although there has been recently remarkable advances in preclinical and

clinical research in era of cancer cachexia, the currently available treatment options are still limited.

8. Nutritional support

Nutritional risk is highest among pancreatic cancer patients.⁵¹ However, despite several trials of conventional and/or aggressive nutritional support using different feeding techniques, the cachectic state is difficult to be overcome by nutritional support alone.⁵² A small multicenter randomized trial for patients with advanced pancreatic cancer showed a meaningful improvement in weight and body mass composition as well as quality of life with L-Carnitine supplementation.⁵³

9. Pharmacologic treatment

The two major options for pharmacological therapy have been, till now, either progestational agents or corticosteroids. Recently, there are various drugs studied for treatment of cancer cachexia.

Megestrol acetate is semi-synthetic progesterone widely used as an appetite stimulant. The pharmacologic activity of megestrol acetate was considered as reduced release of pro-inflammatory cytokines (IL-1, IL-6, TNF- α) and stimulation of NPY in the hypothalamus.^{54,55} Several randomized control trials have demonstrated that megestrol acetate (480-800 mg/ day) significantly improves appetite, nausea, food intake, and weight gain among patients with cancer cachexia, including those with pancreatic cancer.⁵⁶⁻⁵⁹ Megestrol acetate is generally well-tolerated with low incidence of adverse events, such as skin rash, hyperglycemia, adrenal insufficiency, and thromboembolic events.⁵⁷ Since its approval in 1993, several meta-analyses have revealed that megestrol acetate has better effect of improved appetite, weight, and quality of life compared than placebo or other drugs (cisapride, dronabinol, corticosteroids, nandrolone).^{60,61}

Corticosteroids, such as dexamethasone, have been studied to treat cancer-associated anorexia and cachexia.^{62,63} The mechanism of action is likely associated with the inhibition of IL-1, TNF- α , and leptin as well as the stimulation of NPY.⁶⁴ However, the effects of corticosteroid could not be maintained longer than 4 weeks and related to long-term side effects, such as insulin resistance, fluid retention, steroid-induced myopathy, skin fragility, adrenal insufficiency, and sleep and cognitive disorders.⁶⁵ Owing to their short term symptomatic benefits with long term adverse effects, corticosteroids are just considered as treatment option in patients with short expected survival.

Dronabinol is effective in reducing nausea and increasing appetite with a tendency to weight stabilization. The appetite-stimulant effect of dronabinol associated with interaction with endorphin receptors, interference with IL-1 synthesis, activation of cannabinoid receptors involved in the neuronal circuit of leptin and inhibition of prostaglandin synthesis.²⁰ A phase II study showed that dronabinol decreased anorexia in 68% of patients, but 16% of patients had to stop administration due to CNS adverse events, such as euphoria, hallucinations, psychosis, and vertigo.⁶⁶ However, in result of first clinical trial that compared megestrol acetate with dronabinol, megestrol acetate appears to be superior to dronabinol in aspect of increasing appetite and weight gain.⁶⁷ Dronabinol serves as an alternative treatment option as an appetite stimulant and anti-emetic.

Non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2) inhibitors, ibuprofen, and indomethacin, reduce release of acute phase proteins and pro-inflammatory cytokines.^{68,69} NSAIDs are suggested to inhibit prostaglandin synthesis and thereby prevent downstream effects of systemic inflammation. Preliminary results of some studies for NSAIDs, such as indomethacin and ibuprofen, have been shown to effect to increase weight and muscle mass, improve quality of life, and prolong survival in advanced cancer patients, especially when combined with progestogens.⁶⁹⁻⁷² However, further large studies are needed to validate the clinical role of NSAIDs in the management of cancer cachexia.

Thalidomide have anti-inflammatory and immunomodulatory properties that downregulate the production of TNF- α and other cytokines, inhibit NF- κ B, downregulate COX-2, and inhibit angiogenesis.⁷³ In 2005, Gorden et al. published the results of a single center, double blinded, placebo-controlled, randomized study aimed at assessing the efficacy and safety of thalidomide in attenuating weight loss in pancreatic cancer patients with cachexia.⁷⁴ The study population consisted of 50 patients (who had lost at least 10% of their body weight) randomized to administer thalidomide 200 mg/day or a placebo for 24 weeks. The conclusion of the study strongly suggested that thalidomide was effective for attenuating loss of weight and lean body mass in patients with cancer cachexia. Thalidomide was typically well-tolerated. Adverse events included peripheral neuropathy, dizziness, somnolence, constipation, rash, and possible increased risk of venous thromboembolism. These results are significant but further large-scale clinical trials are needed to validate the efficacy of thalidomide in treating pancreatic cancer cachexia.

Cyproheptadine is an antiserotonergic agent with antihistamine properties. Despite some promising results of pilot

studies, controlled clinical trials have not yet proved its efficacy in cancer cachexia patients.^{75,76} Pizotifen is an antiserotonergic drug studied in the treatment of anorexia associated with other benign causes, which has not been investigated in cancer patients.

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid of the omega-3 family, have been revealed to suppress production of pro-inflammatory cytokines, including IL-1, TNF- α , and IL-6.^{77,78} EPA can also inhibit the downstream effect of LMF and PIF.⁷⁹⁻⁸¹ Their efficacy in cancer cachexia has not been fully validated in well-organized clinical trials.⁸²⁻⁸⁴ Two systematic literature reviews conclude the EPA and DHA in monotherapy show no significant improvement in appetite, fat free mass, survival and quality of life compared with placebo.^{85,86} The efficacy of EPA in cancer cachexia treatment remains uncertain although recent study suggest that EPA supplementation may not be effective as a single agent or even in combination with megestrol acetate in patients with cancer cachexia.

Current studies are investigating an approach of drug combinations to attenuate cancer cachexia. A recent data from a large multicenter trial with 332 patients comparing medroxyprogesterone, megestrol acetate, and oral supplementation with EPA, L-carnitine, and thalidomide found that the combination therapy was significantly effective in improving lean body mass and appetite than any other treatment arms with single drug treatment.⁸⁷

10. New therapeutic targets

Due to lack of the available drugs that have shown sustained effects on weight stabilization and improvement in survival, various researches have continued to explore new therapeutic targets and to develop new drugs.

OHR/AVR 118 is a recently developed, broad-spectrum peptide-nucleic acid immunomodulator that target both TNF- α and IL-6. A phase II study including patients with advanced cancer and cachexia presented an improvement in anorexia, dyspepsia, strength and depression.⁸⁸ A phase IIb study is currently underway to evaluate the safety and efficacy of OHR/AVR118 (NCT01206335).

ALD518 (also known as BMS-945429), a humanized monoclonal IL-6 antibody, showed promising beneficial results in phase II randomized, double-blinded, placebo-controlled trials with non-small cell lung cancer (NSCLC) patients with cachexia.^{89,90} This agent was safe and well tolerated. ALD518 has effect of increasing hemoglobin level and preventing loss

of lean body mass with significant improvement of fatigue score.^{89,90}

Ghrelin is the endogenous ligand of the growth hormone receptor that produces the release of growth hormone and NPY.⁹¹ In addition, Ghrelin induces the release of anti-inflammatory cytokine, IL-10, which suppressed the production of pro-inflammatory cytokines, including IL-1 β , IL-6 and TNF- α .⁹²⁻⁹⁴ Several controlled clinical trials using oral ghrelin mimetic named RC-1291 or anamorelin, demonstrated an improvement in increasing appetite and weight in cancer cachexia patients.⁹⁵⁻⁹⁷ Macimorelin is a novel oral ghrelin compound, with a good oral availability and stability, which binds the growth hormone secretagogue receptor (GHSR) 1a with similar affinity to ghrelin.⁹⁸ These findings promoted further investigation for ghrelin analogs and more phase II trials are ongoing (NCT01505764, NCT01614990).

MT-102, a novel anabolic/catabolic transforming agent, has a multi-targeting effect on three potential pharmacological pathways in cancer cachexia, primarily reduced catabolism through nonselective β -blockade, improve fatigue and thermogenesis through blocking central 5-HT 1a receptor, and increased anabolism through partial activation of β -2 receptor.⁹⁹ Two phase II studies in stage III/IV colorectal cancer and NSCLC are under investigation (ACT-ONE and ACT-TWO; NCT01238107).⁹⁹

BYM338 (bimagrumab) is a fully humanized monoclonal antibody blocking the activin II receptor type IIB (ActRIIB) and preventing receptor occupation by myostatin. Myostatin, a member of the TGF- β superfamily, is expressed almost exclusively in skeletal muscle and acts as a negative regulator of muscle growth, through binding to the ActRIIB by activating multiple downstream pathways.¹⁰⁰ Inhibition of muscle differentiation by myostatin is mediated, in part, through Smad 2/3 phosphorylation-dependent inhibition of the Akt/mTOR pathway.¹⁰⁰ In preclinical study, ActRIIB blockade prevented muscle loss and prolonged survival in C-26 tumor-bearing mice.¹⁰¹ A multicenter, randomized, double-blind, placebo-controlled phase II trials to investigate the efficacy of BYM 338 in attenuating loss of body mass in cachectic patients with stage IV NSCLC or stage III/IV pancreatic cancer has been completed and in preparation to report the results (NCT01433263). LY2495655 is another humanized anti-myostatin antibody currently under investigation. A phase II study in patients with locally advanced or metastatic pancreatic cancer is ongoing to evaluate two different doses of LY2495655 in combination with standard of care chemotherapy in improving survival, lean body mass and physical performance (NCT01505530).

CONCLUSION

Although cachexia is a major problem in cancer and many chronic diseases, cachexia treatment is still largely ignored even for inpatient management or limited to dietary counseling to treat weight loss with poor efficacy. Regarding that approximately 80% of pancreatic cancer suffer from cachectic symptoms and up to 30% die from cachexia-related complications, importance of treatment for cancer cachexia, especially in pancreatic cancer patients, should be acquired in the future.^{1,102} Although pancreatic cancer cachexia is considered as multifactorial syndrome mediated by mechanical factors, pro-inflammatory cytokines, neuropeptides, hormones and tumor-derived factors, further researches to understand the basic mechanism involved in induction and maintenance of pancreatic cancer cachexia are further needed. Recently, some preliminary studies for targeted agents have been shown promising results. We hoped that new therapeutic strategies will be developed to improve the quality of life and prolong the survival of pancreatic cancer patients in the future.

REFERENCES

1. Fearon KC, Voss AC, Hustead DS, et al. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. *Am J Clin Nutr* 2006;83:1345-1350.
2. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. *CA Cancer J Clin* 2002;52:72-91.
3. Wigmore SJ, Plester CE, Richardson RA, et al. Changes in nutritional status associated with unresectable pancreatic cancer. *Br J Cancer* 1997;75:106-109.
4. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med* 1980;69:491-497.
5. Mueller TC, Burmeister MA, Bachmann J, et al. Cachexia and pancreatic cancer: are there treatment options? *World J Gastroenterol* 2014;20:9361-9373.
6. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. *Eur J Cancer* 2008;44:1124-1132.
7. Ozola Zalite I, Zyklus R, Francisco Gonzalez M, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. *Pancreatology* 2015;15:19-24.
8. Pausch T, Hartwig W, Hinz U, et al. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. *Surgery* 2012;152:S81-S88.

9. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011;12:489-495.
10. Pannala R, Leibson CL, Rabe KG, et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. *Am J Gastroenterol* 2009;104:2318-2325.
11. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. *Gastroenterology* 2008;134:95-101.
12. Sah RP, Nagpal SJ, Mukhopadhyay D, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. *Nat Rev Gastroenterol Hepatol* 2013;10:423-433.
13. Tisdale MJ. Cachexia in cancer patients. *Nat Rev Cancer* 2002;2:862-871.
14. Imoto A, Mitsunaga S, Inagaki M, et al. Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer. *Int J Cancer* 2012;131:2795-2807.
15. Mitsunaga S, Kinoshita T, Hasebe T, et al. Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. *Pancreas* 2008;36:241-248.
16. Deutsch J, Kolhouse JF. Assessment of gastrointestinal function and response to megestrol acetate in subjects with gastrointestinal cancers and weight loss. *Support Care Cancer* 2004;12:503-510.
17. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. *Lancet Oncol* 2003;4:686-694.
18. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. *Nat Rev Clin Oncol* 2013;10:90-99.
19. Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia pathophysiology and translational aspect of herbal medicine. *Jpn J Clin Oncol* 2013;43:695-705.
20. Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. *Crit Rev Oncol Hematol* 2013;88:625-636.
21. Wisse BE, Frayo RS, Schwartz MW, et al. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. *Endocrinology* 2001;142:3292-3301.
22. Marks D, Cone RD. The role of the melanocortin-3 receptor in cachexia. *Ann N Y Acad Sci* 2003;994:258-266.
23. Marks DL, Butler AA, Turner R, et al. Differential role of melanocortin receptor subtypes in cachexia. *Endocrinology* 2003;144:1513-1523.
24. Scarlett JM, Jobst EE, Enriori PJ, et al. Regulation of central melanocortin signaling by interleukin-1 beta. *Endocrinology* 2007;148:4217-4225.
25. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? *Cancer Res* 1999;59:4493-4501.
26. Shintani F, Kanba S, Nakaki T, et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. *J Neurosci* 1993;13:3574-3581.
27. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. *Science* 2002;297:609-611.
28. Llovera M, Carbo N, Lopez-Soriano J, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. *Cancer Lett* 1998;133:83-87.
29. Li YP, Reid MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. *Am J Physiol Regul Integr Comp Physiol* 2000;279:1165-1170.
30. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. *Science* 2000;289:2363-2366.
31. Zhang HH, Halbleib M, Ahmad F, et al. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. *Diabetes* 2002;51:2929-2935.
32. Ryden M, Arvidsson E, Blomqvist L, et al. Targets for TNF-alpha-induced lipolysis in human adipocytes. *Biochem Biophys Res Commun* 2004;318:168-175.
33. Cawthorn WP, Heyd F, Hegyi K, et al. Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4 (TCF7L2)-dependent pathway. *Cell Death Differ* 2007;14:1361-1373.
34. Hammarstedt A, Isakson P, Gustafson B, et al. Wnt-signaling is maintained and adipogenesis inhibited by TNFalpha but not MCP-1 and resistin. *Biochem Biophys Res Commun* 2007;357:700-706.
35. Moses AG, Maingay J, Sangster K, et al. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. *Oncol Rep* 2009;21:1091-1095.
36. Martignoni ME, Dimitriu C, Bachmann J, et al. Liver macrophages contribute to pancreatic cancer-related cachexia. *Oncol Rep* 2009;21:363-369.
37. Martignoni ME, Kunze P, Hildebrandt W, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. *Clin Cancer Res* 2005;11:5802-5808.
38. Todorov PT, McDevitt TM, Meyer DJ, et al. Purification and characterization of a tumor lipid-mobilizing factor. *Cancer Res* 1998;58:2353-2358.
39. Hirai K, Hussey HJ, Barber MD, et al. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. *Cancer Res* 1998;58:2359-2365.
40. Russell ST, Hirai K, Tisdale MJ. Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. *Br J Cancer* 2002;86:424-428.
41. Tan CR, Yaffee PM, Jamil LH, et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. *Front Physiol* 2014;5:88.
42. Felix K, Fakelman F, Hartmann D, et al. Identification of serum proteins involved in pancreatic cancer cachexia. *Life Sci* 2011;88:218-225.
43. Todorov P, Cariuk P, McDevitt T, et al. Characterization of a cancer cachectic factor. *Nature* 1996;379:739-742.
44. Wigmore SJ, Todorov PT, Barber MD, et al. Characteristics of patients with pancreatic cancer expressing a novel cancer

- cachectic factor. *Br J Surg* 2000;87:53-58.
45. Cariuk P, Lorite MJ, Todorov PT, et al. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. *Br J Cancer* 1997;76:606-613.
46. Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. *Br J Cancer* 2001;84:1135-1140.
47. Whitehouse AS, Tisdale MJ. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. *Br J Cancer* 2003;89:1116-1122.
48. Wyke SM, Tisdale MJ. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. *Br J Cancer* 2005;92:711-721.
49. Eley HL, Tisdale MJ. Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. *J Biol Chem* 2007;282:7087-7097.
50. Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. *Gastroenterol Res Pract* 2011;2011:601434.
51. Bozzetti F, Group SW. Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. *Support Care Cancer* 2009;17:279-284.
52. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. *Clin Nutr* 2008;27:793-799.
53. Kraft M, Kraft K, Gartner S, et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. *Nutr J* 2012;11:52.
54. McCarthy HD, Crowder RE, Dryden S, et al. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. *Eur J Pharmacol* 1994;265:99-102.
55. Mantovani G, Maccio A, Lai P, et al. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. *Semin Oncol* 1998;25:45-52.
56. Bruera E, Macmillan K, Kuehn N, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. *Cancer* 1990;66:1279-1282.
57. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. *J Natl Cancer Inst* 1990;82:1127-1132.
58. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. *J Clin Oncol* 1993;11:762-767.
59. Westman G, Bergman B, Albertsson M, et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. *Eur J Cancer* 1999;35:586-595.
60. Pascual Lopez A, Roquei Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. *J Pain Symptom Manage* 2004;27:360-369.
61. Lesniak W, Bala M, Jaeschke R, et al. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome--a systematic review and meta-analysis. *Pol Arch Med Wewn* 2008;118:636-644.
62. Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. *Br Med J (Clin Res Ed)* 1984;288:27.
63. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. *Cancer Treat Rep* 1985;69:751-754.
64. Plata-Salaman CR. Dexamethasone inhibits food intake suppression induced by low doses of interleukin-1 beta administered intracerebroventricularly. *Brain Res Bull* 1991;27:737-738.
65. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. *J Clin Oncol* 1999;17:3299-3306.
66. Nelson K, Walsh D, Deeter P, et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. *J Palliat Care* 1994;10:14-18.
67. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol* 2002;20:567-573.
68. Preston T, Fearon KC, McMillan DC, et al. Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. *Br J Surg* 1995;82:229-234.
69. Wigmore SJ, Falconer JS, Plester CE, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. *Br J Cancer* 1995;72:185-8.
70. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. *Cancer Res* 1994;54:5602-5606.
71. McMillan DC, O'Gorman P, Fearon KC, et al. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. *Br J Cancer* 1997;76:788-790.
72. McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. *Br J Cancer* 1999;79:495-500.
73. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. *J Exp Med* 1991;173:699-703.
74. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. *Gut* 2005;54:540-545.
75. Couluris M, Mayer JL, Freyer DR, et al. The effect of cyproheptadine hydrochloride (peractin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. *J Pediatr Hematol Oncol* 2008;30:791-797.

76. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. *Cancer* 1990;65:2657-2662.
77. Meydani SN, Lichtenstein AH, Cornwall S, et al. Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. *J Clin Invest* 1993;92:105-113.
78. Wigmore SJ, Fearon KC, Maingay JP, et al. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. *Clin Sci (Lond)* 1997;92:215-221.
79. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. *Biochem Pharmacol* 1991;41:103-107.
80. Tisdale MJ. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. *Nutrition* 1996;12:S31-S33.
81. Hussey HJ, Tisdale MJ. Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. *Br J Cancer* 1999;80:1231-1235.
82. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. *J Clin Oncol* 2003;21:129-134.
83. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. *J Clin Oncol* 2006;24:3401-3407.
84. Persson C, Glimelius B, Ronnelid J, et al. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. *Nutrition* 2005;21:170-178.
85. Dewey A, Baughan C, Dean T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. *Cochrane Database Syst Rev* 2007; CD 004597.
86. Mazzotta P, Jeney CM. Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated fatty acids in the management of symptoms, survival, and quality of life. *J Pain Symptom Manage* 2009;37:1069-1077.
87. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. *Oncologist* 2010;15:200-211.
88. Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. *J Am Med Dir Assoc* 2011;12:62-67.
89. Rigas JR, Schuster M, Orlov SV, et al. Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized double-blind safety and efficacy trial. *J Clin Oncol* 2010;28s:Abstracts 7622.
90. Schuster M, Rigas JR, Orlov SV, et al. ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2010;28s:Abstracts 7631.
91. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999;402:656-660.
92. Gonzalez PV, Cragnolini AB, Schiöth HB, et al. Interleukin-1 beta-induced anorexia is reversed by ghrelin. *Peptides* 2006;27:3220-3225.
93. Waseem T, Duxbury M, Ito H, et al. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. *Surgery* 2008;143:334-342.
94. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. *J Clin Invest* 2004;114:57-66.
95. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. *Oncologist* 2007;12:594-600.
96. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. *J Clin Endocrinol Metab* 2004;89:2832-2836.
97. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. *Support Care Cancer* 2013;21:129-137.
98. Broglio F, Boutignon F, Benso A, et al. EP1572: a novel peptidomimetic GH secretagogue with potent and selective GH-releasing activity in man. *J Endocrinol Invest* 2002;25:RC26-28.
99. Stewart Coats AJ, Srinivasan V, Surendran J, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. *J Cachexia Sarcopenia Muscle* 2011;2:201-207.
100. Ma JD, Heavey SF, Revta C, et al. Novel investigational biologics for the treatment of cancer cachexia. *Expert Opin Biol Ther* 2014;14:1113-1120.
101. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. *Cell* 2010;142:531-543.
102. Bachmann J, Ketterer K, Marsch C, et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. *BMC Cancer* 2009;9:255.